FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
latest-news-card-1
Medical Devices

FDA Alert on Abiomed Impella Controllers

FDA issues an early alert after becoming aware that Abiomed had issued a letter to affected customers recommending certain Automated Impella Controlle...

latest-news-card-1
Human Drugs

FDA Rejects Biogen's High-Dose Spinraza

FDA issues Biogen a complete response letter on a supplemental NDA for a high-dose regimen of Spinraza (nusinersen) for treating spinal muscular atrop...

latest-news-card-1
Human Drugs

FDA Extends Review on Sanofi Multiple Sclerosis NDA

FDA extends by three months its review of Sanofis multiple sclerosis drug tolebrutinib to evaluate additional analyses submitted recently.

latest-news-card-1
Human Drugs

Roches Giredestrant Shows Promise in Breast Cancer

Roche reports positive Phase 3 data with its investigational breast cancer drug giredestrant.

latest-news-card-1
Human Drugs

FDA Issues Guidance on Malaria Drug Development

FDA posts a draft guidance entitled Malaria: Developing Drugs for Treatment that outlines key considerations for companies developing drugs targeting ...

latest-news-card-1
Human Drugs

Lexicon Submits New Data to FDA on Zynquista

Lexicon Pharmaceuticals says FDA is requiring additional time to review its new clinical data submitted earlier this month in an effort to advance its...

latest-news-card-1
Human Drugs

Priority Review for Rare Vision-Loss Disorder Drug

FDA accepts for priority review a Chiesi NDA for idebenone and its use in treating Leber hereditary optic neuropathy.

latest-news-card-1
Medical Devices

Guide on Enforcement Discretion for Emergency-Use IVDs

FDA posts a final guidance outlining how the agency will decide when to temporarily allow use of unapproved diagnostic tests during a declared public ...

latest-news-card-1
Human Drugs

Stealth Wins Approval for Barth Syndrome Drug

FDA grants accelerated approval to a Stealth Biotherapeutics NDA for Forzinity (elamipretide) injection for treating Barth syndrome.

latest-news-card-1
Human Drugs

FDA Rejects sNDA for Rexultis Use in PTSD

FDA rejects Otsuka Pharmaceutical and H. Lundbecks sNDA to expand the use of Rexulti (brexpiprazole) for treating post-traumatic stress disorder in ad...